Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity study of ChimeriVax Japanese encephalitis vaccine in Thai toddlers and children
2015-005193-38Phase 2
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of japanese encephalitis chimeric virus vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Sanofi. Primary endpoint: Number of participants with solicited injection site and systemic reactions after first injection.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2015-005193-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005193-38.